ATXS: Astria Therapeutics, Inc.
About
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.
Current Value
$9.721 Year Return
Current Value
$9.721 Year Return
Key Details
Market Cap
$550.23M
P/E Ratio
-4.66
1Y Stock Return
114.29%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
2.2
Strategies that include ATXS
Stock's related to ATXS
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KYMR | 40.56% | $2.77B | +125.95% | 0.00% |
| KALV | 40.20% | $440.88M | +17.08% | 0.00% |
| ARVN | 40.07% | $1.49B | +4.04% | 0.00% |
| SNDX | 38.75% | $1.35B | +2.87% | 0.00% |
| RCKT | 38.66% | $1.20B | -39.83% | 0.00% |
| CRNX | 37.15% | $5.12B | +84.27% | 0.00% |
| NVRI | 37.04% | $552.13M | +20.03% | 0.00% |
| ARCT | 36.75% | $489.20M | -21.27% | 0.00% |
| PLRX | 36.47% | $778.32M | -9.55% | 0.00% |
| DMRC | 35.97% | $694.39M | -2.06% | 0.00% |
| CLDX | 35.44% | $1.66B | -10.82% | 0.00% |
| SFIX | 35.38% | $480.74M | +11.14% | 0.00% |
| ALEC | 35.35% | $377.04M | -19.46% | 0.00% |
| DAWN | 35.29% | $1.36B | +13.42% | 0.00% |
| BJRI | 35.12% | $780.10M | +11.11% | 0.00% |
| BIGC | 35.09% | $473.42M | -31.75% | 0.00% |
| EDIT | 34.98% | $204.72M | -75.49% | 0.00% |
| PGEN | 34.96% | $228.91M | -28.00% | 0.00% |
| FBIO | 34.76% | $43.83M | -27.73% | 0.00% |
| VRDN | 34.51% | $1.60B | +28.92% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| APD | -0.04% | $72.92B | +18.69% | 2.14% |
| MKC | 0.10% | $20.21B | +15.19% | 2.23% |
| SNY | -0.11% | $120.34B | +3.11% | 4.25% |
| XGN | -0.20% | $62.26M | +127.74% | 0.00% |
| SCM | -0.20% | - | - | 11.60% |
| AMED | -0.20% | $2.95B | -3.95% | 0.00% |
| SOLV | 0.27% | $11.58B | -16.19% | 0.00% |
| PG | -0.27% | $402.15B | +14.14% | 2.33% |
| PSN | -0.29% | $10.03B | +50.06% | 0.00% |
| CYD | -0.29% | $364.46M | -2.94% | 4.26% |
| ADM | -0.39% | $25.34B | -28.13% | 2.82% |
| ARLP | -0.39% | $3.54B | +26.77% | 10.11% |
| MSDL | 0.40% | $1.83B | +0.66% | 7.26% |
| SEVN | 0.42% | $193.74M | +16.70% | 10.77% |
| IMRN | -0.43% | $10.31M | -5.04% | 0.00% |
| IMNN | 0.46% | $10.02M | -22.89% | 0.00% |
| VIV | 0.47% | $14.69B | -9.96% | 0.00% |
| NOAH | -0.49% | $775.22M | -3.69% | 8.96% |
| MBI | 0.50% | $335.78M | +105.79% | 0.00% |
| NHTC | 0.54% | $61.83M | +0.19% | 14.81% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PULM | -18.52% | $19.83M | +202.98% | 0.00% |
| NOC | -15.00% | $71.54B | +4.23% | 1.60% |
| HUSA | -14.33% | $16.69M | -11.56% | 0.00% |
| LMT | -12.96% | $126.40B | +18.99% | 2.36% |
| CBOE | -11.81% | $21.46B | +15.84% | 1.11% |
| TCTM | -9.50% | $8.10M | -42.99% | 0.00% |
| AJG | -9.48% | $64.17B | +17.51% | 0.80% |
| PGR | -9.40% | $149.10B | +57.29% | 0.45% |
| QNTM | -8.71% | $9.19M | -94.36% | 0.00% |
| CME | -8.66% | $82.76B | +9.21% | 1.98% |
| NEUE | -8.34% | $40.93M | -34.13% | 0.00% |
| KO | -8.10% | $269.63B | +7.86% | 3.07% |
| TW | -7.68% | $28.66B | +42.39% | 0.29% |
| BTCT | -7.55% | $42.61M | +353.33% | 0.00% |
| PRT | -7.14% | $48.72M | -16.56% | 10.33% |
| MNOV | -7.03% | $93.19M | +2.15% | 0.00% |
| OXBR | -6.99% | $19.05M | +178.18% | 0.00% |
| LITB | -6.96% | $35.48M | -75.45% | 0.00% |
| STG | -6.91% | $35.67M | +7.92% | 0.00% |
| VIRT | -6.64% | $3.17B | +110.38% | 2.60% |
ETF's related to ATXS
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| RSPA | 52.25% | $273.87M | 0% |
| XPH | 51.26% | $157.87M | 0.35% |
| XBI | 49.70% | $6.58B | 0.35% |
| PBE | 49.15% | $258.53M | 0.58% |
| IBB | 48.75% | $6.66B | 0.45% |
| IWC | 47.85% | $933.99M | 0.6% |
| GNOM | 47.37% | $70.59M | 0.5% |
| PTH | 47.20% | $143.31M | 0.6% |
| ARKG | 46.25% | $1.13B | 0.75% |
| EFAA | 45.85% | $117.38M | 0% |
| IWO | 45.33% | $12.56B | 0.24% |
| VTWO | 44.79% | $12.38B | 0.1% |
| IWM | 44.74% | $75.73B | 0.19% |
| ISCG | 44.42% | $640.00M | 0.06% |
| SMMD | 44.00% | $1.24B | 0.15% |
| ESML | 43.75% | $1.90B | 0.17% |
| NUSC | 43.71% | $1.27B | 0.31% |
| PINK | 43.57% | $161.15M | 0.5% |
| TMSL | 43.42% | $288.12M | 0.55% |
| PRFZ | 43.25% | $2.65B | 0.39% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| DFSD | -0.03% | $3.63B | 0.16% |
| KCCA | -0.35% | $220.51M | 0.87% |
| CANE | 0.82% | $17.72M | 0.29% |
| AGZD | -0.84% | $142.76M | 0.23% |
| KRBN | 0.85% | $242.47M | 0.85% |
| KLIP | 0.86% | $125.85M | 0.93% |
| CLOI | -1.08% | $715.40M | 0.4% |
| KMLM | 1.11% | $353.87M | 0.9% |
| FTSD | 1.13% | $171.68M | 0.25% |
| CORN | 1.15% | $61.12M | 0.2% |
| MINT | 1.20% | $11.62B | 0.35% |
| IVOL | 1.22% | $548.70M | 1.02% |
| USCI | 1.42% | $185.47M | 1.07% |
| HDRO | -2.62% | $164.26M | 0.3% |
| HIGH | 2.64% | $302.78M | 0.51% |
| SOYB | -2.86% | $27.32M | 0.22% |
| BOXX | -3.08% | $4.43B | 0.1949% |
| TBIL | -3.13% | $4.38B | 0.15% |
| XBIL | 3.21% | $637.70M | 0.15% |
| IBTE | 3.33% | $1.70B | 0.07% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -36.27% | $388.04M | 1.43% |
| VIXY | -23.01% | $195.31M | 0.85% |
| USDU | -15.01% | $201.97M | 0.5% |
| UUP | -13.52% | $309.25M | 0.77% |
| TAIL | -12.67% | $67.98M | 0.59% |
| UNG | -10.76% | $908.80M | 1.06% |
| DBA | -9.24% | $755.88M | 0.93% |
| CTA | -8.59% | $350.27M | 0.78% |
| WEAT | -6.26% | $120.27M | 0.28% |
| TPMN | -5.60% | $40.60M | 0.65% |
| EQLS | -5.21% | $76.08M | 1% |
| JUCY | -4.32% | $324.29M | 0.6% |
| FBY | -3.53% | $127.69M | 0.99% |
| TBIL | -3.13% | $4.38B | 0.15% |
| BOXX | -3.08% | $4.43B | 0.1949% |
| SOYB | -2.86% | $27.32M | 0.22% |
| HDRO | -2.62% | $164.26M | 0.3% |
| CLOI | -1.08% | $715.40M | 0.4% |
| AGZD | -0.84% | $142.76M | 0.23% |
| KCCA | -0.35% | $220.51M | 0.87% |
News
Yahoo
BOSTON, November 13, 2024--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.
Yahoo
BOSTON, November 13, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies London Healthcare Conference on Wednesday, November 20th at 12:00pm GMT in London, UK.
Yahoo
BOSTON, November 04, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 210,000 shares of Astria’s common stock on November 1, 2024 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.
Yahoo
BOSTON, October 30, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present interim quality of life results from the ALPHA-STAR trial of navenibart (STAR-0215) at the Canadian Society of Allergy and Clinical Immunology (CSACI) Annual Scientific Meeting in Banff, Alberta, Canada on November 7, 2024.
Yahoo
BOSTON, October 21, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts will present two posters at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting in Boston, Massachusetts on October 25, 2024.
Yahoo
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.